Assessment of airway clearance techniques in adults with bronchiectasis


Patients with bronchiectasis have symptoms of persistent cough and excess sputum production as a result of permanently damaged airways. Respiratory physiotherapy, in particular airway clearance techniques (ACTs), form the cornerstone in the management of bronchiectasis. However, there is a lack of valid and reliable clinimetric outcome measures to evaluate the effectiveness of various ACTs. This study aims to examine the feasibility of electrical impedance tomography in assessing the short-term effects of airway clearance in patients with bronchiectasis.

Trial Status
Not yet recruiting
Trial Phase
Trial contact details
Contact Person
Judy Hough
What you need to know

Who can take part?

Inclusion criteria

  • Has a diagnosis of bronchiectasis
  • Productive of secretions that require routine airway clearance
  • Performs ACTs regularly at home
  • Willing and able to provide informed consent

Exclusion criteria

  • Contraindicated for ACTs, including chest trauma, facial trauma or facial burns, bleeding disorder, uncontrolled bronchospasm, and current haemoptysis.
  • Contraindicated for EIT measurements, including pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps.
  • Inability to follow instructions.
  • Patients less than 18 years of age.

What is involved for you?

Upon consenting to the study, we will collect information from you including your age, gender, time of diagnosis, frequency and routine of ACTs, weight, height, body mass index, and comorbidities. You will also answer a questionnaire to rate how breathlessness you are during daily activities.

Trial dates

1 March - 1 October 2024

All research clinical trials news

Jan Mundt had just celebrated the birth of her first grandchild when she received a devastating cancer diagnosis. Despite having never smoked, Mrs Mundt was told a pain in her chest was being...



Clinical trials help gran defy terminal lung cancer diagnosis

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.



Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.



Highlighting Mater Research’s year of achievements: 2023 Annual Report

Displaying results 1-3 (of 20)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|